Health

OncoSil Medical gains momentum with Q1 FY25 progress

Article Image

OncoSil Medical (ASX:OSL), a medical device company specialising in the treatment of locally advanced pancreatic cancer, recorded a revenue of $166,000 for the first quarter of FY25 ended Sept. 30.
 
This signifies an increase, as the total annual revenue up to the end of September rose to $700,000, compared to $200,000 for the previous year.
 
The company remains committed to expanding its market presence to drive further sales growth.

In a notable development, a patient in Türkiye successfully underwent surgery following treatment with the OncoSil device, highlighting its effectiveness.
 
"The successful resection in Türkiye is a breakthrough moment for OncoSil," stated Nigel Lange, CEO & Managing Director of OncoSil Medical.
 
The Spanish market also saw the completion of its 30th patient treatment using the OncoSil™ device.
 
Twelve sites in Spain are currently operational, with four additional sites ready to commence treatments, illustrating significant market expansion.
 
In addition to its operational successes, OncoSil has achieved a 50% patient recruitment milestone in both its TRIPP-FXX and PANCOSIL clinical trials, crucial for the continued evaluation of the OncoSil device.

OncoSil Medical is a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer.
 
At the time of reporting, OncoSil Medical's share price was $0.0080.

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

Publisher
Grafa